Study:
Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumors
Rationale:
Drugs used in chemotherapy, such as doxorubicin, ifosfamide, and etoposide, work
in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
Giving combination chemotherapy with or without radiation therapy before surgery may make the
tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving
combination chemotherapy after surgery may kill any tumor cells that remain after surgery.
Purpose:
This phase II trial is studying how well combination chemotherapy works in treating
patients with stage III or stage IV malignant peripheral nerve sheath tumors.
Study Status: Recruiting
Recruiting:
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100
| Condition |
Intervention |
Phase |
Neurofibromatosis Type 1 (nf1)
Sarcoma |
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: filgrastim
Drug: ifosfamide
Procedure: conventional surgery
Procedure: radiation therapy |
Phase 2 |
Verified by
Sarcoma Alliance for Research through Collaboration
June, 2007
Sponsored by: Sarcoma Alliance for Research through Collaboration
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00304083
Study Type: Interventional
Study Design: Treatment, Open Label
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Denise Reinke, MS, NP., Principal Investigator
Brigitte C. Widemann, MD., Principal Investigator